A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

- Pathologically documented locally advanced or metastatic solid tumor

- Refractory or intolerant to all available standard-of-care therapies for advanced disease

- Measurable disease

- Adequate tumor sample

- ECOG Performance Status of 0 or 1

- BMI ≥ 18 kg/m2

- Adequate liver, renal, hematologic, and coagulation parameters

- Negative serum pregnancy test (for women of childbearing potential) at Screening and a negative urine or serum pregnancy test on Day 1 prior to the first infusion

- Males and females of childbearing potential must agree to use a highly effective method of contraception during treatment and for at least 4 months after the last dose of study treatment.

- Must be able to understand and comply with the conditions of the protocol and must have read and understood the consent form and provided written informed consent.

- Concurrent anticancer therapy: Radiotherapy, chemotherapy, biological therapy, or other anticancer investigational agents NOTE: at least 5 half-lives must have been ensued for any prior systemic cancer therapy agent before subject received the study drug on Day 1

- Unresolved toxicities from prior anticancer therapy, defined as not having resolved according to CTCAE version 5.0 Grade ≤ 1, excluding Grade 1 alopecia

- Presence or suspicion of active central nervous system (CNS) metastases and/or leptomeningeal carcinomatosis

- Peripheral neurotoxicity ≥ Grade 2 according to CTCAE v5.0

- Known active infection with HIV, HTLV-1, hepatitis B or C

- Women who are pregnant or breastfeeding

- History of another malignancy unless the subject has been treated with curative intent for this malignancy